Archive for Wednesday, April 29, 2009

Cancer vaccine extends survival in study

April 29, 2009

Advertisement

— An experimental treatment added four months to the lives of men with advanced prostate cancer in a study that tested an entirely new approach to fighting the disease, doctors reported Tuesday.

Dendreon Corp.’s Provenge vaccine trains the immune system to fight tumors. It’s called a “vaccine” even though it treats disease rather than prevents it.

Doctors have been trying to develop such a therapy for decades, and this is the first to meet a preset goal for improving survival in late-stage testing.

“There have been a lot of false starts, but this is a real start,” said Dr. Paul Schellhammer, a urologist at Eastern Virginia Medical School in Norfolk, Va., who led the study. Results were reported Tuesday at an American Urological Association conference in Chicago.

Comments

Use the comment form below to begin a discussion about this content.

Commenting has been disabled for this item.